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Education and debate
Academic medicine campaign
Obstacles to conducting epidemiological research in the
UK general population
Hester J T Ward, Simon N Cousens, Blaire Smith-Bathgate, Margaret Leitch, Dawn Everington,
Robert G Will, Peter G Smith
Experiences from a national case-control study of Creutzfeldt-Jakob disease show the tensions
between protecting individual patients’ confidentiality and the access required for the benefit of
public health
Case-control studies are a powerful epidemiological
method for identifying risk factors for disease. They are
generally complex to design and execute. However, the
difficulties of conducting such studies have been
substantially increased by concerns about confidential-
ity and access to medical records. These barriers could
be deleterious to the public’s health. In this article, we
report some of the problems we faced in conducting a
national case-control study of Creutzfeldt-Jakob
disease.
Data protection in the United Kingdom
Advances in computer technology have given rise to
fears about access to patients’ records. The UK
response was to supplement doctors’ common law
duty of confidentiality to their patients with the Data
Protection Act 1998. Much debate has ensued about
the extent to which medical research could be
impeded, including issues surrounding informed con-
sent, patient confidentiality, anonymisation, and access
to data.1 2 The subsequent updating of guidance on
confidentiality by various professional organisations
has produced inconsistencies, adding to the confusion
about what constitutes ethically acceptable research.3–5
Fears have been expressed that epidemiological
research will be severely hampered, and disease
surveillance was severely threatened in England and
Wales before the introduction of section 60 of the
Health and Social Care Act 2001.6
UK case-control study of
Creutzfeldt-Jakob disease
The National Creutzfeldt-Jakob Disease Surveillance
Unit was conducting a national case-control study of
all cases of sporadic Creutzfeldt-Jakob disease before
variant Creutzfeldt-Jakob disease was identified in the
United Kingdom in 1996.7 The study compared the
exposure history of patients with Creutzfeldt-Jakob
disease with that of controls recruited from inpatients
at the same hospitals as the cases. We considered
hospital controls suitable for comparison with cases
for many potential risk factors. However, they were
likely to be unrepresentative of the general population
with respect to their exposure to medical procedures.
The discovery of variant Creutzfeldt-Jakob disease
made identification of iatrogenic risk factors a priority.
We therefore decided to recruit controls likely to be
more representative of the general population in this
respect—namely, people registered with the same gen-
eral practitioner as each case.
Research ethics committee approval
With the Data Protection Act 1998 in its infancy and
uncertainty surrounding its interpretation, there was
concern about how the study could be carried out
without breaching patient confidentiality. We sub-
mitted an application to a multicentre research ethics
committee in July 1998 and obtained approval, after
some amendments, in October 1998. Under the
revised protocol, we would write to the general practi-
tioners of patients with Creutzfeldt-Jakob disease and
ask them to take part in the study. If they agreed, the
general practitioners would be asked to write (using
pre-prepared letters) to 20 people of similar age and
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sex to the case, randomly selected from their patient
database. These individuals were asked to consent to
be contacted by the National Creutzfeldt-Jakob
Disease Surveillance Unit. We then wrote to those who
consented, inviting them to participate in the study
and to nominate a relative to be interviewed. (Because
cases are typically too unwell to participate, a relative
is interviewed, and so we had to do the same for con-
trols.) The relatives of the controls who agreed were
approached, and if they also consented, a nurse
practitioner visited and interviewed them at a conven-
ient location.
As a condition of our ethical approval, we also had
to approach 213 local research ethics committees. This
was because at that time no provision was made for
studies that did not have local researchers. The task was
cumbersome, partly because there was no uniformity
in what was required by each local ethics committee
or in how they discharged their responsibility.2 8–10
Since 2000, studies with no local researcher and that
meet certain conditions are not required to seek
approval from local research ethics committees,
although the above concerns still apply to studies with
local investigators.
Recruiting controls
By September 2003, we had written to 333 general
practices (relating to 109 variant and 224 sporadic
cases). Of these, 328 replied and 243 agreed to take
part in the study (85 (78%) and 158 (71%) for variant
and sporadic cases, respectively). Some of the practices
that refused to participate did not give a reason.Others
just stated that they did not want their patients to par-
ticipate, some were concerned about a potential breach
of patient confidentiality, and others contacted the
families of the cases, who expressed concern about the
practice participating.
The table summarises the response rates of poten-
tial controls and their relatives written to by their gen-
eral practitioner. Overall, 37% (1033/2804) of poten-
tial controls replied to their general practitioner’s
letter, of whom 702 consented to be approached
directly by the surveillance unit. Of 637 controls
written to by the unit by September 2003, 466
consented to take part in the study. Of the 448 relatives
contacted to ask for their consent to be interviewed,
397 (89%) consented. Thus the overall response rate
was 16%.
During 2000, when it was apparent that the
response rate was low, two senior researchers attended
a multicentre research ethics committee meeting to
put the case for telephoning people who had not
responded to a reminder letter from their general
practitioner. We proposed that the initial letter from
the general practitioner would indicate that if the
person did not reply to a reminder letter within a
certain time they would be telephoned by a researcher
from the surveillance unit. The ethics committee
refused this approach on the grounds of breaking
patient confidentiality.
Effect of restrictions
It is now difficult to recruit community based controls
from general practices without introducing scope for a
substantial degree of selection bias, partly because of
the status of patient confidentiality in Europe and the
United Kingdom. In our study, an additional barrier
was created because we could not approach people
unless they had sent written consent to their general
practitioner. We believe this was partly responsible for
the poor initial response rate of 37%.
Another problem was that the ethical approval
required general practitioners to send detailed written
information about the study. An important part of the
process of recruiting people into studies is explaining
to them why the study is important and what is being
asked of them. This is particularly true when the study
is as complicated as ours. We believe that relying on
letters, with no early opportunity for the researchers to
interact directly with potential participants, contrib-
uted to the low response rate.
Our study has an excess of healthcare workers in
the control group, which may bias our results. Because
of the potential for selection bias resulting from the
low response rate, and the complicated logistics
involved, we have had to explore other approaches to
recruiting controls.
Balancing costs to the individual with
benefits to society
We believe that if valid epidemiological research is to
continue, a balance must be found to ensure an appro-
priate degree of patient confidentiality without making
it impossible to conduct research into questions with
overall benefit for society. The potential gain to the
wider public from the results of individual studies must
be considered. In addition, we need a debate about the
efficient use of public funds for research in relation to
patient confidentiality. The cost of recruiting each con-
trol in this study was considerable (about £1100
(€1650, $2000) compared with £300 for each case), but
the low response rate will inevitably limit our
conclusions. Should the effective use of public funds be
given more weight in the ethics committee decision
making process?
Alternative ethical approaches
Alternative approaches to recruiting community
controls include using publicly available databases,
picking random houses in a street, or asking cases (or
their relatives) to nominate a relative or friend. Each of
these has advantages and disadvantages. The use of
publicly available databases—for example, telephone
Recruitment of controls and their relatives for a case-control study of variant and
sporadic Creutzfeldt-Jakob disease (CJD) by the national surveillance unit
No of people (% of those written to)
Variant CJD Sporadic CJD Total
Controls written to by general practitioner 1673 1131 2804
Replied to letter 409 (24) 624 (55) 1033 (37)
Consented to be contacted 312 (19) 390 (34) 702 (25)
Controls written to by unit 304 333 637
Replied to letter 228 (75) 262 (79) 490 (77)
Consented to participate 220 (72) 246 (74) 466 (73)
Relatives written to by unit 214 234 448
Replied to letter 193 (90) 213 (91) 406 (91)
Consenting to participate 188 (88) 209 (89) 397 (89)
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directory listings or the postcode address file, raises an
interesting issue. People on these databases can be (and
are) approached by researchers or salespeople without
any ethical approval, although research funded within
the health service will usually require that ethical
approval is obtained. However, health researchers are
not permitted to contact directly individuals who have
not replied to a letter from their general practitioner
because their name has been obtained from a general
practice list.
If we had contacted individuals who had not
responded to a letter from their general practitioner
(to which they could have responded indicating that
they did not wish to be contacted) would this have con-
stituted an unacceptable breach of patient confidenti-
ality or an unacceptable infringement of their privacy?
Further debate is needed on how to strike an
appropriate balance between an individual’s rights and
freedoms and the right of the community or society to
answer important questions. Perhaps patients of
general practitioners should have the opportunity to
opt out of being contacted for health research
purposes in the same way as some private companies
offer customers the opportunity to indicate that they
do not want their names passed on to other interested
parties.
This study would not have been possible without the
cooperation of the relatives of patients with Creutzfeldt-Jakob
disease and controls and their relatives. We thank research staff
at the unit for collecting data (M Zeidler, G Stewart, M A
Macleod, C Henry, A Lowman, S Cooper, C Heath, K Murray)
and N Attwood for database management.
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Summary points
Issues of patient confidentiality are hampering
epidemiological research
Wider debate is required about the use of medical
records to identify eligible individuals
Ethics committees should weigh the benefits to
society against costs to the individual when
considering studies
Use of public funds should be considered
as part of the cost to society if a study
cannot recruit participants by the most effective
method
When Dr Mopp tried to get into research
Initially, it had all seemed so easy and straightforward.
Working in a large children’s hospital, I thought it
would be useful to survey paediatric nurses and
doctors about their knowledge of popular children’s
television characters. Knowing one’s Tweenies from
one’s Fimbles always helps in communicating with a
wary preschool child, and it would be interesting to
find out just how much paediatric healthcare
professionals knew about these things. Filling out a
little questionnaire would be a bit of fun for everyone
involved. But fun and research don’t always make easy
friends, as I was soon to learn.
One of my colleagues wisely suggested that it would
make sense to survey a few young hospitalised children
as a control group. This sounded like good advice, but
that’s when the trouble started. In order to be able to
ask a few children whether they recognised Tinky
Winky or Jake, I was told I had to apply for approval
from the ethics committee. In order to obtain this
approval, I had to seek statistical advice. The statistician
asked me to do a pilot study first to establish how
many children would be needed for my project.
Having done so, I finally filled out the rather lengthy
ethical approval application form. After all this, I was
told today that the form has changed as from this
month to a new nationwide form.
If you never read this study written up in any journal
don’t be surprised. Mind you, I will add it to my
portfolio as an extremely interesting learning
experience in politically correct research.
Markus Hesseling specialist registrar in paediatrics, Alder
Hey Children’s Hospital, Liverpool
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